Omthera Pharmaceuticals, Inc. Stockholders Seeking More Money, Information in Buyout Should Contact Deans & Lyons Law Firm
30 Maio 2013 - 7:01PM
PR Newswire (US)
DALLAS, May 30, 2013 /PRNewswire/ -- Securities
lawyers at Deans & Lyons announced an investigation of the
board of Omthera Pharmaceuticals, Inc. (NASDAQ: OMTH) for a
proposed sale to AstraZeneca. OMTH investors are encouraged to
contact attorney Hamilton Lindley at 877-819-8033 or
hlindley@deanslyons.com about their rights and remedies.
Although at least one analyst estimated the value could reach
$15 per share before the deal was
announced, OMTH stockholders will receive only $12.70 per share upon the acquisition by
AstraZeneca. The investigation seeks to ensure OMTH stockholders
obtain the highest price reasonably available in this buyout in
addition to the disclosure of all important information.
The securities lawyers of Deans & Lyons have significant
experience representing investors nationwide in representative
actions involving securities at no cost to its clients.
Stockholders with concerns about this OMTH stock or anyone with
information about this transaction should contact Hamilton Lindley
at hlindley@deanslyons.com or 877-819-8033.
Hamilton Lindley
Deans & Lyons LLP
325 N. Saint Paul Street, Suite
1500
Dallas, TX 75201
(877) 819-8033 Toll Free
(214) 965-8500 Telephone
(214) 965-8505 Facsimile
hlindley@deanslyons.com
deanslyons.com
SOURCE Deans & Lyons LLP
Copyright 2013 PR Newswire
OMTHERA PHARMACEUTICALS, INC. (NASDAQ:OMTH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
OMTHERA PHARMACEUTICALS, INC. (NASDAQ:OMTH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Omthera Pharmaceuticals, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Deans & Lyons LLP